Home > Insider Trading > Filing (0001209191-17-039532)

Filing Details

Accession Number:: 0001209191-17-039532
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-06-13 17:03:37
Reporting Period:: 2017-06-12

Filing Date:: 2017-06-13
Accepted Time:: 2017-06-13 17:03:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1123494	Harvard Bioscience Inc	HBIO	Laboratory Analytical Instruments (3826)	043306140

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1585223	Jeffrey Duchemin	Harvard Bioscience, Inc. 84 October Hill Road Holliston MA 01746	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-06-12	22,000	$2.76	810,984	No	4	P	Direct
Common Stock	Disposition	2017-06-12	22,000	$2.66	788,984	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	S	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $2.70 to $2.80. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 128,427 shares of common stock held by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $2.65 to $2.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 106,427 shares of common stock held by the Reporting Person.